Evotec SE (EVO)
USD 4.29
(1.42%)
USD 4.29
(1.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 222.55 Million EUR | 84.15% |
| 2022 | 153.21 Million EUR | 39.46% |
| 2021 | 109.86 Million EUR | 48.51% |
| 2020 | 73.97 Million EUR | 26.72% |
| 2019 | 58.37 Million EUR | 18.6% |
| 2018 | 49.22 Million EUR | 12.15% |
| 2017 | 43.89 Million EUR | 101.29% |
| 2016 | 21.8 Million EUR | -46.18% |
| 2015 | 40.51 Million EUR | 48.77% |
| 2014 | 27.23 Million EUR | 0.68% |
| 2013 | 27.05 Million EUR | -11.94% |
| 2012 | 30.72 Million EUR | 0.24% |
| 2011 | 30.64 Million EUR | 12.81% |
| 2010 | 27.16 Million EUR | -28.57% |
| 2009 | 38.03 Million EUR | -39.76% |
| 2008 | 63.13 Million EUR | 10.3% |
| 2007 | 57.23 Million EUR | 6.49% |
| 2006 | 53.74 Million EUR | 48.23% |
| 2005 | 36.25 Million EUR | 212.61% |
| 2004 | -32.19 Million EUR | 12.32% |
| 2003 | -36.72 Million EUR | -53.58% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 58.98 Million EUR | -5.14% |
| 2024 Q1 | 62.17 Million EUR | -0.18% |
| 2023 Q1 | 40.72 Million EUR | -9.04% |
| 2023 Q2 | 82.61 Million EUR | 102.87% |
| 2023 Q4 | 62.29 Million EUR | 24.58% |
| 2023 FY | 282.13 Million EUR | 84.15% |
| 2023 Q3 | 49.99 Million EUR | -39.48% |
| 2022 Q3 | 41.94 Million EUR | 21.01% |
| 2022 Q1 | 31.83 Million EUR | -14.27% |
| 2022 Q2 | 34.66 Million EUR | 8.9% |
| 2022 Q4 | 44.77 Million EUR | 6.72% |
| 2022 FY | 153.21 Million EUR | 39.46% |
| 2021 FY | 109.86 Million EUR | 48.51% |
| 2021 Q2 | 23.4 Million EUR | -2.08% |
| 2021 Q1 | 23.9 Million EUR | 19.07% |
| 2021 Q3 | 25.42 Million EUR | 8.66% |
| 2021 Q4 | 37.13 Million EUR | 46.02% |
| 2020 FY | 73.97 Million EUR | 26.72% |
| 2020 Q4 | 20.07 Million EUR | 1.61% |
| 2020 Q3 | 19.75 Million EUR | 16.4% |
| 2020 Q2 | 16.97 Million EUR | -1.2% |
| 2020 Q1 | 17.17 Million EUR | -4.11% |
| 2019 Q1 | 12.59 Million EUR | -8.84% |
| 2019 Q4 | 17.91 Million EUR | 41.94% |
| 2019 Q3 | 12.62 Million EUR | -17.25% |
| 2019 Q2 | 15.25 Million EUR | 21.08% |
| 2019 FY | 58.37 Million EUR | 18.6% |
| 2018 Q2 | 12.47 Million EUR | 4.36% |
| 2018 Q4 | 13.81 Million EUR | 25.93% |
| 2018 FY | 49.22 Million EUR | 12.15% |
| 2018 Q1 | 11.95 Million EUR | 9.89% |
| 2018 Q3 | 10.97 Million EUR | -12.07% |
| 2017 Q3 | 14.23 Million EUR | 46.63% |
| 2017 FY | 43.89 Million EUR | 101.29% |
| 2017 Q4 | 10.88 Million EUR | -23.55% |
| 2017 Q2 | 9.7 Million EUR | 7.0% |
| 2017 Q1 | 9.07 Million EUR | 424.7% |
| 2016 Q2 | 7.88 Million EUR | -5.08% |
| 2016 Q3 | 8.4 Million EUR | 6.52% |
| 2016 Q4 | -2.79 Million EUR | -133.25% |
| 2016 FY | 21.8 Million EUR | -46.18% |
| 2016 Q1 | 8.31 Million EUR | 1.0% |
| 2015 Q2 | 11.32 Million EUR | 14.16% |
| 2015 Q4 | 8.22 Million EUR | -25.47% |
| 2015 FY | 40.51 Million EUR | 48.77% |
| 2015 Q1 | 9.92 Million EUR | -6.21% |
| 2015 Q3 | 11.04 Million EUR | -2.54% |
| 2014 Q2 | 7.26 Million EUR | -10.3% |
| 2014 Q4 | 10.58 Million EUR | 713.85% |
| 2014 FY | 27.23 Million EUR | 0.68% |
| 2014 Q1 | 8.09 Million EUR | 76.86% |
| 2014 Q3 | 1.3 Million EUR | -82.1% |
| 2013 Q3 | 7.52 Million EUR | -3.4% |
| 2013 Q2 | 7.78 Million EUR | 8.61% |
| 2013 Q1 | 7.16 Million EUR | -29.67% |
| 2013 FY | 27.05 Million EUR | -11.94% |
| 2013 Q4 | 4.57 Million EUR | -39.14% |
| 2012 Q1 | 8.05 Million EUR | -5.39% |
| 2012 Q3 | 7.07 Million EUR | 1.39% |
| 2012 Q4 | 10.19 Million EUR | 44.17% |
| 2012 FY | 30.72 Million EUR | 0.24% |
| 2012 Q2 | 6.97 Million EUR | -13.4% |
| 2011 Q3 | 7.57 Million EUR | 8.86% |
| 2011 Q1 | 8.36 Million EUR | -24.68% |
| 2011 Q4 | 8.51 Million EUR | 12.31% |
| 2011 FY | 30.64 Million EUR | 12.81% |
| 2011 Q2 | 6.96 Million EUR | -16.73% |
| 2010 Q3 | 5.15 Million EUR | -9.7% |
| 2010 Q1 | 6.11 Million EUR | 952.15% |
| 2010 FY | 27.16 Million EUR | -28.57% |
| 2010 Q2 | 5.7 Million EUR | -6.61% |
| 2010 Q4 | 11.1 Million EUR | 115.32% |
| 2009 Q2 | 10.25 Million EUR | -32.35% |
| 2009 Q3 | 7.91 Million EUR | -22.84% |
| 2009 Q4 | 581 Thousand EUR | -92.65% |
| 2009 FY | 38.03 Million EUR | -39.76% |
| 2009 Q1 | 15.15 Million EUR | -18.07% |
| 2008 Q4 | 18.49 Million EUR | 29.99% |
| 2008 FY | 63.13 Million EUR | 10.3% |
| 2008 Q3 | 14.22 Million EUR | 1.5% |
| 2008 Q2 | 14.01 Million EUR | -14.59% |
| 2008 Q1 | 16.41 Million EUR | -34.19% |
| 2007 Q4 | 24.94 Million EUR | 71.58% |
| 2007 Q3 | 14.53 Million EUR | 202.09% |
| 2007 Q2 | -14.24 Million EUR | 0.0% |
| 2007 Q1 | - EUR | -100.0% |
| 2007 FY | 57.23 Million EUR | 6.49% |
| 2006 Q3 | 8.56 Million EUR | 2.21% |
| 2006 FY | 53.74 Million EUR | 48.23% |
| 2006 Q4 | 22.78 Million EUR | 165.92% |
| 2006 Q1 | 8.88 Million EUR | 5.93% |
| 2006 Q2 | 8.38 Million EUR | -5.7% |
| 2005 Q4 | 8.39 Million EUR | 0.0% |
| 2005 Q1 | 8.44 Million EUR | 31.91% |
| 2005 Q2 | 9.03 Million EUR | 6.99% |
| 2005 Q3 | - EUR | -100.0% |
| 2005 FY | 36.25 Million EUR | 212.61% |
| 2004 Q2 | 8.82 Million EUR | 14.88% |
| 2004 FY | -32.19 Million EUR | 12.32% |
| 2004 Q1 | 7.68 Million EUR | 16.62% |
| 2004 Q3 | - EUR | -100.0% |
| 2004 Q4 | 6.4 Million EUR | 0.0% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | 5.94 Million EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | -36.72 Million EUR | -53.58% |
| 2003 Q4 | 6.58 Million EUR | 10.79% |
| 2002 FY | -23.91 Million EUR | -87.72% |
| 2001 FY | -12.73 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -13.56% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -396.183% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -39.791% |
| Cosmos Health Inc. | 26.18 Million USD | -750.081% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -957.68% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 18.146% |
| Cronos Group Inc. | 96.7 Million USD | -130.132% |
| Incannex Healthcare Limited | 30.05 Million USD | -640.552% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -468.432% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -353.848% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -5476.304% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1595.748% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1595.748% |
| SCYNEXIS, Inc. | 51.84 Million USD | -329.251% |
| Safety Shot Inc | 12.1 Million USD | -1737.85% |
| Theratechnologies Inc. | 72.75 Million USD | -205.896% |
| Alpha Teknova, Inc. | 45.85 Million USD | -385.309% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1507.856% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 31.81% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2256.108% |
| Dynavax Technologies Corporation | 219.14 Million USD | -1.557% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 4.121% |
| Radius Health, Inc. | 265.92 Million USD | 16.309% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -7151.364% |
| Alvotech | 285.43 Million USD | 22.029% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 62.279% |
| SIGA Technologies, Inc. | 22.04 Million USD | -909.653% |
| Shineco, Inc. | 17.94 Million USD | -1140.013% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -29088.241% |
| Journey Medical Corporation | 54.59 Million USD | -307.66% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1149.727% |
| Embecta Corp. | 528.4 Million USD | 57.881% |
| Harrow Health, Inc. | 89.97 Million USD | -147.361% |
| Procaps Group, S.A. | 199.47 Million USD | -11.571% |
| Biofrontera Inc. | 39.95 Million USD | -456.966% |
| DURECT Corporation | 43.71 Million USD | -409.111% |
| PainReform Ltd. | 9.58 Million USD | -2222.183% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 57.929% |
| OptiNose, Inc. | 85.1 Million USD | -161.519% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2427.769% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 29.152% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -417.089% |
| ProPhase Labs, Inc. | 37.85 Million USD | -487.969% |
| Phibro Animal Health Corporation | 260.29 Million USD | 14.499% |
| Procaps Group S.A. | 187.24 Million USD | -18.859% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2165.221% |
| Viatris Inc. | 5.96 Billion USD | 96.27% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1347.626% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -271.922% |
| Tilray Brands, Inc. | 251.35 Million USD | 11.457% |
| PetIQ, Inc. | 192.72 Million USD | -15.48% |
| Talphera, Inc. | 11.99 Million USD | -1755.578% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 86.06% |
| Alimera Sciences, Inc. | 62.64 Million USD | -255.291% |
| Assertio Holdings, Inc. | 368.58 Million USD | 39.618% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -3681.417% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -34.911% |
| Hempacco Co., Inc. | 7.59 Million USD | -2829.764% |
| Alvotech | 285.43 Million USD | 22.029% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 35.472% |
| Kamada Ltd. | 45.42 Million USD | -389.935% |
| Currenc Group, Inc. | 24 Million USD | -827.244% |
| Indivior PLC | 911 Million USD | 75.57% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1693.428% |
| Flora Growth Corp. | 10.57 Million USD | -2003.772% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -957.68% |
| Evolus, Inc. | 189.75 Million USD | -17.285% |
| HUTCHMED (China) Limited | 436.23 Million USD | 48.982% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -44.393% |
| Akanda Corp. | 3.48 Million USD | -6288.905% |